Hans H Shuhaiber

Hans H Shuhaiber, M.D.

Clinical Assistant Professor

Department: MD-NEUROLOGY-GENERAL SERVICES
Business Phone: (352) 294-5000
Business Email: hshuhaiber@ufl.edu

About Hans H Shuhaiber

The Center for Excellence in Care in Neurofibromatosis at UF HEALTH provides comprehensive and exceptional care for patients and families affected with NF. We are designated clinic as a member of the NFCN ( Neurofibromatosis Clinical network). We also members of the NF Foundation and Network.

Hans H Shuhaiber MD , provides the individualized treatment you need if you’ve been diagnosed with this complex and lifelong condition.

At UF Health, we offer comprehensive treatment and management options for all types of neurofibromatosis, a relatively rare genetic disorder that affects the development of nerve cells and sometimes causes tumors (neurofibromas) to develop in the nervous system.

At UF Health, our patients benefit not just from a single neurofibromatosis specialist, but from the expertise of an entire team of experts. We do not require referrals, and all of our diagnostic, treatment, and supportive care services are available in a single, convenient location. Through our unique approach, each patient has the advantage of receiving several expert opinions from our neurofibromatosis specialist team in one comfortable and familiar place.

Each neurofibromatosis specialist on UF Health multispecialty tumor team has highly focused skills and experience. Consider that:

-Our UF Health neurosurgeons and surgical oncologists address nerve tumors with a high level of precision using advanced, minimally invasive surgical techniques, which also allow them to access difficult-to-reach neurofibromas that have developed near-critical nerve pathways.

-Our UF Health radiation oncologists and medical oncologists incorporate nonsurgical treatment options, such as chemotherapy and radiation therapy, into highly individualized treatment plans, as appropriate.

– Our UF Health supportive care specialists provide a variety of services, including education, counseling, and nutritional support, to help ensure the best possible quality of life for our patients both during and after treatment.

Each neurofibromatosis specialist at UF Health is committed to treating, educating, and supporting individuals who have been diagnosed with this uncommon condition.

If you are a patient or family suffering from Neurofibromatosis. Please contact me directly at hshuhaiber@ufl.edu. I am looking forward to personally helping you with the long-life illness of Neurofibromatosis. We are available for your NF needs 24/7. We accept all insurance plans, and we accept patients as well with no insurance. We are running several investigational clinical trials that would help your underlying NF disease.

Related Links:

Teaching Profile

Courses Taught
2018
MDC7124 Family Med/Geriatrics
2021
MDC7800 Neurology Clerkship
Teaching Philosophy
Education in Neurofibromatosis and lectures for residents, medical students

Clinical Profile

Specialties
  • Neurology
Areas of Interest
  • Adrenoleukodystrophy
  • Brain tumor – primary – adults
  • Chromosome
  • Down syndrome
  • Genetics
  • Hypokalemic periodic paralysis
  • Multiple sclerosis
  • Multiple system atrophy – cerebellar subtype
  • Myasthenia gravis
  • Neurofibromatosis 2
  • Neurofibromatosis-1
  • Tuberous sclerosis

Research Profile

Hans H. Shuhaiber MD, is running industry-sponsored clinical trials to help patients with complex pain issues caused by Plexiform neurofibroma. Please send me an email at hshuhaiber@ufl.edu to evaluate your eligibility for a clinical trial. https://neurology.ufl.edu/divisions/neurofibromatosis-center/neurofibromatosis-clinical-trials/

Areas of Interest
  • Genetic Counseling
  • Genetics of Neurological diseases
  • Neuro-cutaneous Syndromes
  • Population Health
Open Researcher and Contributor ID (ORCID)

0000-0002-1329-3856

Publications

2022
Management of Cavernous Sinus Thrombosis Following Herpes Zoster Ophthalmicus.
Cureus. [DOI] 10.7759/cureus.21036. [PMID] 35155004.
2022
Presumptive Diagnosis of Pallister-Hall Syndrome Using Magnetic Resonance Imaging
Cureus. [DOI] 10.7759/cureus.21735. [PMID] 35251807.
2021
Cryptococcosis Presenting as Cerebrovascular Disease.
Cureus. [DOI] 10.7759/cureus.19442. [PMID] 34926024.
2021
Moyamoya Disease in a Young Female With Neurofibromatosis Type 1.
Cureus. [DOI] 10.7759/cureus.19121. [PMID] 34858759.
2021
Tetrasomy 18p Initially Misdiagnosed as Cerebral Palsy in an Adult Patient.
Cureus. [DOI] 10.7759/cureus.20053. [PMID] 34993029.
2006
Fetal deformations: a risk factor for obstetrical brachial plexus palsy?
Pediatric neurology. [PMID] 16996396.
2004
Bilateral decreased oxygenation during focal status epilepticus in a neonate with hemimegalencephaly.
Journal of child neurology. [PMID] 15224715.
2004
Cerebral regional oxygen fluctuations and decline during clinically silent focal electroencephalographic seizures in a neonate.
Journal of child neurology. [PMID] 15526959.
2004
Intrauterine shoulder weakness and obstetric brachial plexus palsy.
Pediatric neurology. [PMID] 15351026.
2004
The role of palmaris muscle tendon in mitral valve annulus reconstruction: a novel technique for mitral valve repair.
The heart surgery forum. [PMID] 15799937.
2003
Plantaris tendon graft for atrioventricular valve repair: a novel hypothetical technique.
Texas Heart Institute journal. [PMID] 12638670.

Grants

Jan 2022 ACTIVE
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects with Cutaneous Neurofibromas
Role: Principal Investigator
Funding: SYMBIO
Nov 2021 ACTIVE
A Phase III, Multicentre, International Study with a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants with NF1 who have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)
Role: Principal Investigator
Funding: DRUGDEV INC via ASTRAZENECA
Nov 2020 ACTIVE
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity
Role: Principal Investigator
Funding: MEDPACE via SPRINGWORKS THERAPEUTICS
Mar 2020 ACTIVE
UF HEALTH NEUROMEDICINE HOSPITAL
Role: Principal Investigator
Funding: CHILDRENS TUMOR FOU

Contact Details

Phones:
Business:
(352) 294-5000
Emails:
Business:
hshuhaiber@ufl.edu
Addresses:
Business Mailing:
1505 SW ARCHER RD
GAINESVILLE FL 32608
Business Street:
1505 SW Archer Road
NMH Neurology clinic
GAINESVILLE FL 32608